Adverse reactions in the Paxlovid group (≥ 1%) that occurred at a greater frequency than in the placebo group were diarrhoea (3.9% and 1.9%, respectively), vomiting (1.3% and 0.3%) and dysgeusia (4.8% and 0.1%).
Tabulated summary of adverse reactions: The adverse reactions in Table 6 are listed as follows by system organ class and frequency. Frequencies are defined as follows: Very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); not known (frequency cannot be estimated from the available data). (See Table 6.)
Click on icon to see table/diagram/image
Paediatric population: The safety and efficacy of Paxlovid in paediatric patients have not been established.
Reporting of suspected adverse reactions: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
View ADR Monitoring Form